Bulletin
Investor Alert

London Markets Open in:

The New York Post Archives | Email alerts

Sept. 26, 2020, 11:33 a.m. EDT

Novavax stock soars after start of late-stage COVID-19 vaccine trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)
  • X
    AstraZeneca PLC ADR (AZN)
  • X
    Pfizer Inc. (PFE)

or Cancel Already have a watchlist? Log In

By Noah Manskar


Getty Images
Three potential coronavirus, COVID-19, vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19.

Novavax’s stock price surged Friday after the biotech firm started a key late-stage trial of its experimental coronavirus vaccine.

Shares in the Maryland-based company soared nearly 11 percent to $113.56 following its Thursday announcement that it kicked off the Phase 3 study in the United Kingdom, which is battling a surge in COVID-19 infections.

The trial aimed at proving whether Novavax’s /zigman2/quotes/202614340/composite NVAX -7.32%  vaccine is safe and effective will enroll up to 10,000 people over the next four to six weeks, the company said. The participants will range in age from 18 to 84 years old, with half getting two shots of the vaccine, known as NVX-CoV2373, and the other half receiving a placebo.

“With a high level of [coronavirus] transmission observed and expected to continue in the UK, we are optimistic that this pivotal Phase 3 clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373’s efficacy,” Dr. Gregory M. Glenn, Novavax’s president of research and development, said in a statement.

Data from the trial will support Novavax’s applications for regulatory approval in the UK, the European Union and other countries, Glenn added. Novavax said it plans to publish the study’s full protocol in the coming days.

Phase 3 trials are currently underway in the US and Europe for four other potential coronavirus vaccines, including candidates from AstraZeneca /zigman2/quotes/200304487/composite AZN -1.19% , Pfizer /zigman2/quotes/202877789/composite PFE -1.09% , /zigman2/quotes/205619834/composite MRNA -4.12%   and Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -0.43%  .

Pfizer and Moderna have said they could know by October or November whether their vaccines work, but US officials don’t expect a shot to be widely available until next year.

See a lso: There are four coronavirus vaccines in late-stage studies — here’s how they differ

This article was first published on NYPost.com

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 91.16
-7.20 -7.32%
Volume: 3.40M
Oct. 21, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$6.03 billion
Rev. per Employee
$90,470
loading...
/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 51.57
-0.62 -1.19%
Volume: 8.22M
Oct. 21, 2020 4:00p
P/E Ratio
62.89
Dividend Yield
2.66%
Market Cap
$137.21 billion
Rev. per Employee
$342,432
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 37.08
-0.41 -1.09%
Volume: 18.01M
Oct. 21, 2020 4:02p
P/E Ratio
14.75
Dividend Yield
4.10%
Market Cap
$208.33 billion
Rev. per Employee
$580,595
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 68.37
-2.94 -4.12%
Volume: 4.61M
Oct. 21, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$28.14 billion
Rev. per Employee
$177,721
loading...
/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 143.93
-0.62 -0.43%
Volume: 5.22M
Oct. 21, 2020 4:00p
P/E Ratio
22.62
Dividend Yield
2.81%
Market Cap
$380.57 billion
Rev. per Employee
$603,509
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.